Detection and monitoring of driver mutations by next‐generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR‐tyrosine kinase inhibitors

Driver mutation detection and the development of targeted drugs have significantly improved survival of advanced lung adenocarcinoma patients with driver mutations. However, we still lack understanding of druggable mutations in patients with advanced squamous cell lung cancer (SQCLC). Less than 10%...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Xiaoyan, Shen, Jie, Zhang, Hang, Cheng, Yuxin, Yang, Yang, Gao, Jiahui, Zhang, Yu, Li, Rutian, Liu, Baorui, Wang, Lifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754292/
https://www.ncbi.nlm.nih.gov/pubmed/29143497
http://dx.doi.org/10.1111/1759-7714.12551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754292/
https://www.ncbi.nlm.nih.gov/pubmed/29143497
http://dx.doi.org/10.1111/1759-7714.12551

Ejemplares similares